1. Scrip
  2. >>Advanced Therapies

Stoke Gets Runway, Biogen A Late-Stage Asset In Epilepsy Collaboration

 
• By Joseph Haas

Biogen will pay $165m up front for ex-North American rights to Stoke’s Phase III-ready Dravet syndrome candidate, an antisense drug offering disease-modifying potential.

Epilepsy
Stoke is partnering with Biogen on its antisense candidate for a rare type of epilepsy

In what observers are calling a sensible deal for both sides, Stoke Therapeutics and Biogen revealed on 18 February that they will collaborate on development and commercialization of Stoke’s antisense oligonucleotide (ASO) therapy for Dravet syndrome, zorevunersen (STK-001). The deal brings Stoke added financial runway and an experienced commercial partner that has succeeded with ASO therapies, while Biogen obtains a late-stage candidate that may offer blockbuster sales in an underserved rare disease.

Key Takeaways
  • Stoke is partnering its Phase III-ready Dravet syndrome candidate with Biogen in a deal that brings Stoke increased financial runway and an ideal commercial partner...

Cambridge, MA-based Stoke reported encouraging Phase I/IIa data for zorevunersen last March indicating that its drug demonstrated an ability to address the underlying cause of Dravet,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Advanced Therapies

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 
• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

 
• By Alaric DeArment

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Atara Does An About Face As FDA Lifts Ebvallo Hold

 
• By Alaric DeArment

The biotech said it will have a type A meeting with the agency to resubmit for the cell therapy’s approval in EBV+ PTLD.

More from Therapy Areas

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.